Beckman Coulter Diagnostics Showcases The New DxN VERIS Molecular Diagnostics System At The 2015 EuroMedLab

Designed to Revolutionise the Clinical laboratorywith Streamlined Workflow for Improved Productivity

Beckman Coulter Diagnostics is showcasing its revolutionary DxN VERIS Molecular Diagnostics System at Innovations to Improve Workflow for the Diagnostics Laboratory, booth D23 and D24 at the IFCC-EFLM EuroMedLab, 22-24 June 2015, Palais des Congrès, Paris, France.

“The DxN VERIS Molecular Diagnostics System is designed to revolutionise the clinical laboratory with LEAN workflow and improved sample turn-around time,” said Arnd Kaldowski, president, Beckman Coulter Diagnostics. “The system’s true single sample random access empowers laboratories to perform viral load tests whenever they want, at a time that suits them—ultimately helping physicians make faster clinical decisions and positively impacting the patient pathway.

“The robust DxN VERIS can run up to 20 assays at any time,” Kaldowski continues. “This enables laboratories to optimise workflows and staffing productivity, freeing up time, for example, to bring additional and new testing in-house, for laboratory service expansion and to increase reference site revenue potential.”

With LEAN principles at its core, DxN VERIS combines sample prep, nucleic acid extraction, reaction setup, real-time PCR amplification, detection and results interpretation in one instrument, streamlining workflow for improved productivity. “With DxN VERIS we have significantly reduced the need for manual intervention, enabling labs to go from a sample to auto-verified result in just 70 minutes,” said Richard Creager, senior vice president, Molecular Diagnostics Business Unit and chief scientific officer at Beckman Coulter Diagnostics.

Fully CE-marked, the system is available with assays for Human Immunodeficiency Virus (HIV-1), Hepatitis C Virus (HCV), Hepatitis B Virus (HBV) and Human Cytomegalovirus (CMV). Further menu expansion will follow with many other assays currently in development.

DxN VERIS assays are supplied in a unique, single cartridge system so, unlike traditional batch-plate systems, there are no empty wells, reducing wastage and consumable costs. With the DxN VERIS Molecular Diagnostics System, all necessary consumables and reagents are on-board, so there is no lengthy set-up and tests can be up and running in less than 10 minutes.

In addition to featuring the DxN VERIS Molecular Diagnostics System at the exhibition booth, Beckman Coulter will be presenting:

Workflow Transformed: DxN VERIS a New Fully Automated System for Molecular Diagnostics

Monday, 22 June | Room 242
EduW n. 10

Chair: Pr. Jacques lzopet
Director of Virology Department, University Hospital Purpan, Toulouse, France
Head of Core Lab in Hospital Purpan, Toulouse
Director INSERM Unit U1043
National Reference Center for HAV and HEV

Workflow Study Approach

Speaker: Andrew Williams
Managing Partner
Nexus Global Solutions, Inc. (NEXUS), USA

An EU Laboratory Perspective: Spain

Speaker: Pr. Jordi Vila
Director of Microbiology Department
Hospital Clinic de Barcelona, Spain

An EU Laboratory Perspective: UK

Speaker: Dr. Duncan Whittaker
Laboratory Manager
Department of Virology
Sheffield, UK

For more information, visit www.beckmancoulter.com/moleculardiagnostics.

About Beckman Coulter
Beckman Coulter Diagnostics develops clinical diagnostic products that help advance and optimize the clinical laboratory. Beckman Coulter’s instruments, systems and tests help streamline processes to enhance efficiency, reduce costs and speed the delivery of results. For 80 years, Beckman Coulter has been a global leader devoted to providing solutions to laboratories of all sizes—offering a broad portfolio of chemistry, immunoassay, haematology, urinalysis, microbiology, automation, information systems and molecular diagnostics. Beckman Coulter is dedicated to advancing healthcare for every person and moving science, innovation and the lab forward. For more information, visit www.beckmancoulter.com.

About the DxN VERIS Molecular Diagnostics System and Assays
The DxN VERIS Molecular Diagnostics System is a fully automated sample‐to‐answer instrument for the quantitative analysis of molecular targets. It integrates sample introduction, nucleic acid extraction, reaction setup, real‐time PCR amplification and detection (using TaqMan chemistry), and results interpretation for a fully streamlined workflow. A sample tube is simply loaded onto the DxN VERIS Molecular Diagnostics System and all steps after that are performed automatically, giving molecular diagnostics laboratories the freedom and control to provide the right answers at the right time.

The growing menu of assays for use on the DxN VERIS Molecular Diagnostics System includes the CE-marked DxN VERIS CMV Assay (for the quantitative determination of human Cytomegalovirus (CMV) in plasma), DxN VERIS HBV Assay (for quantitative measurement of Hepatitis B Virus (HBV) in human plasma and serum) and DxN VERIS HCV Assay (for quantitative measurement of Hepatitis C Virus (HCV) in human plasma and DxN VERIS HIV-1 Assay (for quantitative detection of Human Immunodeficiency Virus type 1 (HIV-1) in plasma).

Beckman Coulter is committed to ongoing growth and aims to rapidly expand the DxN VERIS Molecular Diagnostics System menu and has many other assays in development.